Skip to content
#gene editing Open access

Triple-Target CRISPR Strategy to Block HIV Entry and Replication in Permissive Cells.

Aug 2026 · Human Gene Therapy · pp. 10430342261463565 · 0 citations
Medicine

Abstract

Total elimination of replication-competent human immunodeficiency virus type 1 (HIV-1) remains a major clinical challenge, in part due to random integration of the proviral DNA into host cell chromosomes, which enables lifelong persistence and production of progeny. Although antiretroviral therapies (ARTs) suppress viral replication, they cannot eliminate integrated proviral DNA, which remains a fundamental obstacle to achieving a cure. To overcome this problem, we developed a combinatorial clustered regularly interspaced short palindromic repeats-Cas9 gene editing strategy to disrupt viral replication and inactivate host factors essential for HIV-1 entry and spread. This approach targets C-C chemokine receptor type 5 (CCR5), a chemokine receptor central to HIV-1 host cell entry, and mannosyl-oligosaccharide glucosidase (MOGS), a key enzyme in glycoprotein processing that modifies the HIV-1 envelope glycoprotein gp120, facilitating receptor engagement, viral entry, and morphogenesis of infectious virion. We demonstrate that our strategy, which includes editing of the integrated proviral DNA, in concert with two cellular genes whose products facilitate viral entry, results in robust suppression of viral replication in vitro and in ex vivo-infected cells. Using transmission electron microscopy, HIV-1 p24 ELISA, and GFP-based viral infection assays, we show that the combination knockout of CCR5, MOGS, and viral sequences profoundly reduces HIV-1 replication in an ex vivo cellular model, that is, HIV-1-infected peripheral blood mononuclear human cells, thus offering a pathway to launch further preclinical studies.

Read PDF

Similar papers

#gene editing Review Sep 2026

Unlocking non-model organisms with CRISPR-Cas: A roadmap for sustainable biotechnology.

It is concluded that bridging the gap between foundational CRISPR research and its real-world applications is imperative and future efforts should focus on democratizing tools via open-source platforms, advancing delivery systems, and fostering sustainable innovation through synthetic biology integration to fully realize the transformative potential of genome editing in organisms beyond model organisms.

S. Sarsaiya, Archana Jain, Jishuang Chen et al. · 2 citations
#gene editing Aug 2026

Genomics and crop improvement: focus on gene editing and its regulation

The future of crop improvement using GEd technologies lies in the harmonisation or alignment of global policies and regulations to support the trade of agricultural produce and ensure that growers and consumers can benefit from GEd technology.

Michael G. K. Jones · 0 citations
#gene editing Review Open access Aug 2026

Immune cell development from human pluripotent stem cells.

The landmark derivation of induced pluripotent stem cells (iPSCs) sparked an enormous range of research on development of diverse cell populations. Perhaps no aspect of this work has been as productive as studies on blood and immune cell production. Indeed, essentially all human blood cell populations can be derived from human iPSCs. While derivation of transplantable hematopoietic stem cells (HSCs) from iPSCs has been relatively challenging, clinical translation of iPSC-derived immune cells has been particularly productive. Notably, more patients have been treated with iPSC-derived natural killer (NK) cells than any other iPSC-derived cell type. Use of iPSCs provides a key platform to incorporate multiplexed gene edits before differentiation, enabling NK cells to be engineered with tumor-targeting CARs, cytokine support for improved persistence, enhanced tumor trafficking, and resistance to host immune rejection, modifications uniformly expressed across the entire cellular product. While T cells, macrophages and other immune cells can be produced from human iPSCs, iPSC-derived NK cells have been the most widely used in clinical trials for treatment of refractory malignancies, as well as autoimmune disease. This review summarizes research with a focus on clinical translation of iPSC-derived immune cells, as well as highlights continued challenges and prospects of this field.

Luisjesus S Cruz, Alejandro R. Castañeda, Dan S Kaufman · 0 citations
#gene editing Review Open access Aug 2026

Beyond Mixed Utilization: Fractionation, Functional Divergence, and Precision Applications of Soybean 7S and 11S Globulins.

Soybean β-conglycinin (7S) and glycinin (11S) differ markedly in their structure, physicochemical properties, and bioactivity; however, industrial practice still treats them as a mixed ingredient, obscuring their differentiated functional potential. This review critically evaluates fractionation technologies through the lens of the "purity-yield-sustainability" trilemma. First-generation chemical precipitation methods achieve high purity at the laboratory scale but suffer from heavy reagent use, environmental burden, and poor scalability. Second-generation green and physical techniques, such as phytase-assisted, membrane-based, and field-assisted separation, improve sustainability but face challenges in fouling control, process stability, and scale-up. Third-generation upstream strategies, including breeding and gene editing, fundamentally alter the 7S/11S ratio at the source, potentially bypassing downstream tradeoffs. Functionally, 7S globulin excels in regulating lipid metabolism and reducing obesity and non-alcoholic fatty liver disease, whereas 11S globulin shows advantages in blood pressure regulation and cardiovascular protection. Structurally, 7S exhibits favorable emulsification and foaming capacities, whereas 11S dominates gel network formation, supporting diverse applications from plant-based foods to nanocarriers and biodegradable films. Future breakthroughs lie in AI-guided hybrid separation systems, data-driven process optimization, and direct linking of fractionation outcomes to end-use functionality. Moving beyond mixed utilization toward precision deployment, soybean 7S and 11S globulins can evolve from bulk commodities into high-value resources for sustainable food systems and precision health applications.

Shuyin Hu, Yuyang Huang, Ya-Qi Lu et al. · 0 citations

Related blog posts

MIT News · Artificial Intelligence Aug 17, 2026

Q&A: Rethinking how innovation happens

In his latest book, Professor Eugene Fitzgerald examines the forces that turn breakthroughs into value — and why innovation resists simple formulas.